Tolerx reached a clinical milestone in its collaboration with Genentech, as that company recently moved a modified version of TRX1, MTRX1011A, an anti-CD4 monoclonal antibody, into a Phase I clinical trial. The trial is evaluating the safety and tolerability of both single and multiple doses of MTRX1011A. Under the terms of the collaboration agreement between Tolerx and Genentech, Tolerx realized milestones in the first quarter of this year upon selection of the antibody for further developme...